Game On: Revance Therapeutics Initiates Phase 3 Trial of Topical Botox
Will Revance's RT001 be the first topically neurotoxin treatment?
Tag: Revance
All
PopularAll
Latest
Crown Laboratories Acquires Revance Therapeutics, Expanding Aesthetic Portfolio
The deal expands Crown’s presence in the aesthetics market, bringing Daxxify and the RHA Collection into its portfolio.
All
Latest
New Short-Term Botox-Like Treatment Moves Closer to FDA Review
The neurotoxin is characterized by a rapid onset of action as early as eight hours after administration and a shorter duration of effect of two to three weeks.
Revance Therapeutics Inc Announces Study Results and a License Agreement for RT002
Revance Therapeutics Inc, a Newark, Calif-based developer of neuromodulators for the treatment of aesthetic and therapeutic conditions, announces two pieces of company news regarding RT002.
Read MoreHot Stuff: November 2015
JUVEDERM ULTRA XC for lips and Coolscupting’s new Coolmini for the double chin are among November’s “Hot Stuff.”
Read More